Antibacterial Agents TRIZ Cases

Modified oxazolidinone targeting Mycobacterium tuberculosis reduces mitochondrial protein synthesis inhibition and myelosuppression risk.

Non-viable silicified replicas preserve pathogenic or tumor-cell structures to support antigen presentation and stronger immune activation.

Rationally designed lawsone derivatives target MSSA and drug-resistant MRSA, including biofilms, while improving the resistance profile.

Pillar[5]arene binds microbial quorum signals non-covalently, reducing Gram-negative virulence while avoiding direct toxicity to human and animal cells.

Light-activated Ligularia fischeri extract generates ROS to reduce bacteria and fungi, including antibiotic-resistant strains.

Unencapsulated lytic proteins target complex mycobacterial envelopes to help reach intracellular bacteria and improve treatment access.

Single- or dual-component nutrition may miss synergistic effects; this formulation combines three biological components for gut and immune benefits.

Cyclodextrin inclusion complexes stabilize TLR2 agonist formulations while improving solubility and bioavailability for nasal or inhaled treatment.

Humanized Hu-mAb 2-5 binds and neutralizes Stx2, addressing ineffective therapies and adverse reactions while reducing kidney damage in HUS models.

D66 disrupts bacterial membrane voltage to inhibit growth and biofilms without permeabilizing membranes or significantly harming mammalian cells.

Oxygen carriers and prodrugs create an aerobic intestinal lumen to inhibit anaerobic bacteria without specialized equipment.

FimH-targeting monoclonal antibodies block bacterial binding to epithelial mannose, reducing urinary-tract bacterial titers without directly killing bacteria.

A D-lactic acid and cosolvent formulation keeps aqueous vancomycin stable, supports dilution flexibility, and simplifies IV handling.

Biofilm resistance limits conventional antibiotics; lyophilized quaternary ammonium formulations enable reconstitutable topical treatment.

A muco-adhesive matrix releases thymol and carvacrol over three days, targeting vaginal infection biofilms from a single application.

Covalently bonded PD-1×LAG-3 diabodies block two inhibitory pathways to sustain T-cell proliferation and cytokine production.

Bacterial proteases cleave peptide linkers at infection sites, releasing antibacterial agents while limiting plasma degradation and off-target effects.

Fusion polypeptides link target antigens with immune-stimulating peptides to strengthen responses despite poor immunogenicity and tolerance.

Simultaneous tetravalent dengue and hepatitis A vaccination addresses serostatus-testing barriers while supporting protection across dengue serotypes.

Combines anti-PD-1 binding with a TGF-β receptor domain to block two suppressive pathways and improve tumor immune-cell activity.

Pre-formulated vancomycin hydrochloride with citric acid and preservatives avoids reconstitution and reduces contamination risk.

Low-shear hollow fibers sequester activated leukocytes and platelets, while citrate inhibits inflammatory mediator release.

See how polysorbate 20 replaces polysorbate 80 to stabilize pneumococcal conjugates and reduce aggregation in 15-valent vaccine formulations.

Silver(II) carboxylates disperse in a carrier base to preserve antimicrobial action, whiteness, and stability under UV exposure.

PD-L1/PD-1 and CD80/PD-L1 interactions suppress immunity; macrocyclic compounds block both to restore T cell activation.

PcrV- and Psl-binding molecules bypass antibiotic resistance pathways by blocking toxin delivery and biofilm formation.

Albumin-binding domains combine CD19 and CD3 targeting with longer in vivo persistence, addressing rapid BiTE® clearance in B-cell malignancy treatment.

Small-molecule biochemical compositions modulate markers linked to inflammation, amyloid-β plaques, iron deposition, and hyperglycemia.

Ionizing irradiation replaces unreliable filtration and antibiotic-salt processing to sterilize bacterial minicells while preserving potency and targeting.

Defined empty liposomes with cholesterol and sphingomyelin help disrupt biofilms and increase microbial susceptibility to antimicrobials.

Bovine adaptive immunity can take at least a week; intra-mammary CATH2 peptide delivery primes innate immune memory for faster pathogen response.

Irradiation inactivates Staphylococcus while antioxidants protect immunogenic epitopes from oxidative damage during vaccine preparation.

Humanized antibodies selectively inhibit FcγRIIA activity to reduce autoimmune responses while preserving other Fcγ receptor functions.

Drug resistance and microbiome disruption challenge Neisseria therapy; selective borate compounds inhibit or kill pathogenic strains while sparing commensals.

An implanted pump delivers bortezomib directly into brain tumors, bypassing the blood-brain barrier and limiting systemic toxicity.

Sclerostin binding agents inhibit bone resorption while promoting bone formation, helping maintain bone density with stable calcium levels.

Tailored solutes and solvents weaken extracellular biofilm matrices near colonized discs, helping dislodge or lyse protected bacteria without surgery.

Novel heterocyclic compounds address limited treatment options for drug-resistant Acinetobacter baumannii infections.

Synthetic peptides face protease degradation and short half-life; nanoparticles help retain antibacterial activity.

Zinc porphyrin permeabilizes bacterial cells and biofilms, enabling antibiotic and phage uptake against resistant infections.

Domain-engineered phage lysin chimeras target P. acnes while preserving commensal bacteria and improving soluble expression for acne treatment.

Mutated SpA, Hla, LukE, Aur, and SAR 2723 antigens remove harmful binding or toxic functions while preserving immunogenicity for S. aureus vaccines.

Formula I compounds inhibit USP25 and USP28, addressing the lack of effective small molecules for modulating protein homeostasis in disease.

Specific inhibitors of Cathepsin C, CELA1, and CELA3A target necrosis pathways at lower concentrations than non-specific elastase inhibitors.

A 2-thioethyl ester linkage anchors unique lipids to polymyxin peptides, improving Gram-negative activity despite poor cell-envelope permeability.

An aqueous-oil lotion uses localized antimicrobial delivery to treat canine hot spots while limiting antibiotic resistance and environmental drawbacks.

Using NITE BP-693 or NITE BP-694, the composition sensitizes MRSA to antibacterial drugs and reduces virulence.

Functional redundancy between mycobacterial oxidases can limit treatment; these inhibitors disrupt oxidative phosphorylation and sensitize bacteria to bactericidal drugs.

Modified penem compounds inhibit L,D- and D,D-transpeptidases, addressing limited efficacy and toxicity in TB and NTM treatment.

Isolated proteinaceous factors from probiotic culture supernatants inhibit EHEC and Salmonella colonization and infection.

Segmented dendrimer synthesis reduces purification time while bridged polycyclic compounds inhibit microbial adhesion.

Bicyclic heteroaryl compounds inhibit Acetyl-CoA carboxylase to regulate fatty acid synthesis and oxidation.

A pyrrolo-quinoxalinone compound structure targets bacterial cells to inhibit growth.

A biodegradable polymer matrix sustains brimonidine release from intraocular implants for extended therapeutic periods.

Fixed-dose tricyclic benzoxaborole combinations reduce multi-drug resistance emergence and shorten treatment duration.

Oxidized squalene derivatives in Chlamydia vaccines accelerate antibody affinity maturation, overcoming weak immune responses in vulnerable populations.

Triscationic compounds eradicate pre-established biofilms by disrupting bacterial membranes, overcoming antibiotic resistance.

An anti-autoimmune reagent binds to pathogenic anti-desmoglein autoantibodies.

Zinc ions amplify borate/polyol antimicrobial efficacy, eliminating conventional preservatives and reducing corneal toxicity risks.

Combining carvacrol with amoxicillin reduces required doses, lowering toxicity while maintaining bactericidal action against resistant bacteria.

Specific furanone and lactam compounds resist Pseudomonas sp. and E. coli biofilm formation to prevent surface contamination.

5-Chlorobenzothiazolone derivatives block KMO to reduce neurotoxic metabolites and increase KYNA, addressing high mortality in acute pancreatitis.

Specific FabI inhibitor compounds enhance bacterial membrane penetration and reduce efflux to treat pneumonia caused by resistant Gram-negative pathogens.

C-7 isoxazolinyl quinolone derivatives provide broad-spectrum antimicrobial activity against pathogenic microorganisms.

Hydroxypropylmethylcellulose matrices control radezolid release kinetics, maintaining systemic concentrations above minimum inhibitory levels.

Rapid ethanol extraction stabilizes isolated walnut extracts against degradation for up to 24 months.

Recombinant TF1 polypeptide binds Shiga toxin type 2 to block eukaryotic cell receptor interaction.

Conserved surface-exposed proteins in vaccine compositions induce protective antibodies, resolving the trade-off between type b protection and NTHi coverage.

siRNAs and antibodies silence or block TEM8 and CMG2 receptors, preventing anthrax toxin entry during late-stage infections.

Engineered M. haemolytica vector delivers protective antigens to resolve inconsistent vaccine immunity.

Quaternary cationic surfactant enhances silver ion antimicrobial activity against biofilms while reducing cell toxicity and skin irritation.

Formula I pyrimidine compounds selectively target Staphylococcus aureus while minimizing resistance development in other bacterial strains.

Structural modifications of a balasubramide derivative inhibit TNF-α and IL-1β, reducing mortality from sepsis-induced acute lung injury.

PlySs2 lysin degrades bacterial cell walls to enable antibiotic penetration, reducing resistance development and side effects.

A mouth freshener composition combines Curcuma longa, Piper longum, and Mentha arvensis extracts to provide antimicrobial action.

N2,N4-disubstituted quinazoline diamines inhibit bacterial dihydrofolate reductase to kill Acinetobacter baumannii.

Formula I compounds bypass active transport resistance by accumulating in cells through optimized lipophilicity.

Specific R-group modifications on the pleuromutilin core improve metabolic stability while sustaining antimicrobial activity against bacteria.

hb-MSC conditioned medium with VEGF above 4000 pg/ml resolves culture variability.

Solid-phase agents capture toxic alkylating residues to maintain pathogen inactivation efficiency without harming biologics.

A monoclonal antibody binds alpha-toxin to prevent abscess formation.

Multiple deletion strain bacteria produce plasmid DNA with lower endotoxin contamination.

Sucrose and sodium chloride create a protective matrix that prevents analog formation in catechol-containing cephalosporins.

Antibodies block GITR ligand binding to reduce Treg suppressive function, restoring effector T cell activity against cancer.

Modifying substituents on the pyrrolidine ring optimizes pharmacokinetic profiles while maintaining therapeutic efficacy for narcolepsy treatment.

A bacterial mixture of Bacillus and lactic acid strains treats podal infections in ungulates, replacing toxic chemicals to eliminate environmental pollution.

Polyethylene glycol chains prevent calcium precipitation of myo-inositol pentakisphosphate, enabling toxin cleavage.

Modified glycopeptide antibiotics restore antimicrobial effectiveness against resistant pathogens by targeting altered lipid II precursors.

Novel 7-deoxy-2-heptulose derivatives inhibit bacterial and fungal growth through targeted enzyme blocking.

Freeze-dried fecal microbiota preserves cell viability during long-term ambient storage, resolving access timing constraints.

Sulfobutylether-beta-cyclodextrin complexes posaconazole with EDTA chelator, preventing precipitation and maintaining stability at 4 mg/mL concentration.

Programmable nucleases cut specific microbial genomes to reduce infection loads rapidly while preserving beneficial microbiota.

Substituted quinoline derivatives with tertiary nitrogen atoms inhibit bacterial growth.

Segmenting the molecule into a CpG first strand and a complementary second strand protects against degradation while maintaining TLR9 recognition.

Triazole compounds inhibit proinflammatory cytokine release, addressing safety limitations of monoclonal antibody therapies.

Optimized physicochemical parameters enhance topical skin penetration of melanocortin receptor modulators, minimizing systemic exposure and side effects.